Enhanced Prediction Model for Major Adverse Events Following Acute Myocardial Infarction
1 other identifier
observational
1,544
1 country
1
Brief Summary
Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide. Although early revascularization has markedly improved short-term outcomes, the incidence of major adverse cardiovascular events after the index event remains unacceptably high, posing a formidable clinical challenge. Contemporary risk-stratification instruments rely predominantly on a restricted set of conventional clinical variables and therefore fail to capture the full spectrum of individual pathophysiological complexity. To overcome these limitations, the present investigation aims to develop a post-AMI prognostic model that integrates comprehensive multimodal data.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 18, 2025
CompletedFirst Posted
Study publicly available on registry
November 26, 2025
CompletedStudy Start
First participant enrolled
December 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
November 26, 2025
September 1, 2025
1.8 years
November 18, 2025
November 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Recurrent myocardial infarction or cardiac death
Patients received recurrent myocardial infarction or cardiac death
At 24-month Follow-up
Diagnostic performance
Diagnostic performance of the AI-driven multimodal predictive model: area under the receiver-operating characteristic curve (AUC), sensitivity, specificity, overall accuracy, positive predictive value (PPV), and negative predictive value (NPV).
At 24-month follow-up
MACE at 24 months
Major adverse cardiovascular events, defined as a compisite of cardiac death, myocardial infarction, target vessel revascularization.
At 24-month follow-up
Secondary Outcomes (1)
MACE at 60 months
At 60-month follow-up
Other Outcomes (2)
MACE according to pre-specified subgroups
At 24- and 60-month follow-up
MACE according to physiological status
At 24- and 60-month follow-up
Study Arms (1)
MI group
Patients who present with myocardial infarction and undergo successful percutaneous coronary intervention will be eligible for enrollment.
Interventions
Eligibility Criteria
Patients with myocardial infarction
You may qualify if:
- Age ≥18 years old
- Presented with myocardial infarction, including NSTEMI and STEMI
- Undergoing successful percutaneous coronary intervention.
You may not qualify if:
- Subjects who decline protocol-mandated follow-up or withhold informed consent.
- Individuals whose expected survival is \< 1 year.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 60 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 18, 2025
First Posted
November 26, 2025
Study Start
December 1, 2025
Primary Completion (Estimated)
September 30, 2027
Study Completion (Estimated)
December 31, 2028
Last Updated
November 26, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share